Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 6/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | AKT2 | P31751 | 1/20 | 0.51 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4778449 | 0.94 | HDAC8 (0.57) | MC4RHDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL4773293 | 0.92 | HDAC8 (0.51) | MC4RHDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL4773213 | 0.90 | HDAC8 (0.51) | MC4RHDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL4775830 | 0.84 | HDAC8 (0.68) | MC4RHDAC8AKT1AKT2AKT3 | |
| SCHEMBL4775840 | 0.83 | HDAC8 (0.45) | MC4RHDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL4904798 | 0.83 | HDAC8 (0.48) | MC4RHDAC8DPP4DPP8DPP9 | |
| SCHEMBL4778400 | 0.83 | HDAC8 (0.56) | MC4RHDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL4779328 | 0.82 | HDAC8 (0.71) | MC4RHDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL4777046 | 0.82 | HDAC8 (0.60) | MC4RHDAC8AKT1AKT2AKT3 | |
| SCHEMBL16380911 | 0.81 | HDAC8 (0.61) | MC4RHDAC8HDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | MC4R 1782/4885HDAC8 16/4885HDAC1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.